[Federal Register: June 17, 2004 (Volume 69, Number 116)]
[Notices]               
[Page 33904-33905]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17jn04-55]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-04-66]

 
Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 498-1210.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Send comments to Seleda Perryman, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-E11, 
Atlanta, GA 30333 or send an e-mail to omb@cdc.gov. Written comments 
should be received within 60 days of this notice.

Proposed Project

    Validating Autism Surveillance Methodology in Metropolitan Atlanta 
Developmental Disabilities Surveillance Program (MADDSP)--New--National 
Center on Birth Defects and Developmental Disabilities (NCBDDD), 
Centers for Disease Control and Prevention (CDC).

Background

    MADDSP was established in 1991 as an ongoing active surveillance 
system for select developmental disabilities (mental retardation, 
cerebral palsy, vision impairment, and hearing loss) in 3 to 10 year 
old children. In 1996, autism spectrum disorders (ASD) was added to 
MADDSP due to growing concern about the prevalence of the condition. 
MADDSP defines ASD as a constellation of social, communicative,

[[Page 33905]]

and behavioral impairments consistent with the DSM-IV-TR diagnostic 
criteria for Autistic Disorder, Asperger's Disorder, and Pervasive 
Developmental Disorders not otherwise specified.
    MADDSP relies on an extensive review of records to identify 
children with an ASD. Potential case records are identified from 
multiple sources which are likely to maintain evaluation or treatment 
records for children with ASD. Pertinent ICD-9, DSM-IV codes and 
predetermined behavioral descriptions are used to trigger records for 
abstraction. Clinical experts then review the abstracted data and 
determine case status based on a behavioral coding scheme that is in 
accordance with the DSM-IV-TR definition for Pervasive Developmental 
Disorders.
    This record review methodology for ASD surveillance has been 
executed and is being used; however, the method is not currently 
validated by a clinical sample which is considered the gold standard 
for identifying ASD. For this reason, it is important to validate 
surveillance methods in a clinical sample in order to determine whether 
current surveillance methodology accurately captures prevalence 
estimates for this developmental outcome. The sensitivity and 
specificity of MADDSP will be measured using judgments from the 
clinical exam as the gold standard. The results from this study will 
provide important implications for how ASD surveillance is maintained.
    Primary caregivers of children already identified through 
surveillance methods will be contacted, informed of the study, and 
asked to participate through an invitation letter and/or telephone 
contact. Clinic visits will be scheduled for all children whose primary 
caregiver agrees to take part in the study and who signs a written 
informed consent; child assent will be obtained at the time of the 
clinic visit. Data collection methods will consist of: (1) Parental 
questionnaires, which will focus on questions about their child's 
behavior and developmental history; and, (2) a developmental evaluation 
for the child participant, which includes a play based assessment 
specific to ASD and a measure of cognitive development. There is no 
cost to respondents.
    Annualized Burden Table:

----------------------------------------------------------------------------------------------------------------
                                                                    No. of      Avg. burden per
             Survey instruments                    No. of       responses per    response  (in     Total burden
                                                respondents       respondent         hours)           hours
----------------------------------------------------------------------------------------------------------------
Parental questionnaires.....................             250                1                3              750
Child developmental evaluation measures.....             250                1                2              500
                                             ------------------
    Total...................................  ...............  ...............  ...............            1250
----------------------------------------------------------------------------------------------------------------


    Dated: June 10, 2004.
Alvin Hall,
Director, Management Analysis and Services Office Centers for Disease 
Control and Prevention.
[FR Doc. 04-13710 Filed 6-16-04; 8:45 am]

BILLING CODE 4163-18-P